Tonix Pharmaceuticals Holding Corp. Share Price Today: Live Updates & Key Insights
Tonix Pharmaceuticals Holding Corp. share price today is $13.55, up -4.08%. The stock opened at $13.72 against the previous close of $13.98, with an intraday high of $13.8383 and low of $13.29.
Tonix Pharmaceuticals Holding Corp. Share Price Chart
Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp. Share Price Performance
Tonix Pharmaceuticals Holding Corp. Institutional Holdings
Tonix Pharmaceuticals Holding Corp. Market Status
Tonix Pharmaceuticals Holding Corp. Fundamentals
Market Cap 190.19 M
PB Ratio 0.7734
PE Ratio 0.0579
Enterprise Value -10.85 M
Total Assets 162.89 M
Volume 255084
Tonix Pharmaceuticals Holding Corp. Company Financials
About Tonix Pharmaceuticals Holding Corp. & investment objective
Company Information Tonix Pharmaceuticals Holding Corp. operates as a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of unmet medical needs and focuses on developing and commercializing therapeutics to treat and prevent human disease. The company's flagship product, TONMYA" (cyclobenzaprine HCl sublingual tablets 2.8 mg), therapy is used for the treatment of fibromyalgia. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as immunology, infectious disease, and rare disease product candidates. The company's products pipeline include TNX-102 SL (cyclobenzaprine HCl sublingual tablet), for the management of fibromyalgia; and is being developed to prevent and treat acute stress reaction, posttraumatic stress disorder, Alzheimer's disease, alcohol use disorder, and multi-site pain associated with Long COVID. It also develops TNX-1300, a double-mutant cocaine esterase, which is in Phase 2 clinical trials for the treatment of cocaine intoxication; and TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, as well as for social anxiety disorder. In addition, the company develops TNX-1500, an Fc-modified humanized monoclonal antibody indicated to prevent organ transplant rejection, as well as to treat autoimmune conditions; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; TNX-801 that is in the pre-IND development stage for protection against smallpox and mpox; and TNX-1800, a live virus vaccine for SARS-CoV-2. Its rare disease portfolio consists of TNX-2900, an intranasal potentiated oxytocin to treat for Prader-Willi syndrome. The company has collaboration agreement with Bilthoven Biologicals to advance TNX-801 and Makana Therapeutics, Inc. to study TNX-1500 for human-compatible
Organisation Biotechnology
Employees 81
Industry Biotechnology
CEO Dr. Seth Lederman M.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:
Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*
Take your next step
